[go: up one dir, main page]

NO20093536L - Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab - Google Patents

Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab

Info

Publication number
NO20093536L
NO20093536L NO20093536A NO20093536A NO20093536L NO 20093536 L NO20093536 L NO 20093536L NO 20093536 A NO20093536 A NO 20093536A NO 20093536 A NO20093536 A NO 20093536A NO 20093536 L NO20093536 L NO 20093536L
Authority
NO
Norway
Prior art keywords
vinflunine
trastuzumab
cancer therapy
therapy including
combination cancer
Prior art date
Application number
NO20093536A
Other languages
English (en)
Norwegian (no)
Inventor
Bart Vanhauwere
Marie-Claire Pinel
Francois-Michel Delgado
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38353425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20093536(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NO20093536L publication Critical patent/NO20093536L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20093536A 2007-05-31 2009-12-16 Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab NO20093536L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290679A EP1997534A1 (fr) 2007-05-31 2007-05-31 Thérapie de combinaison de traitement du cancer comportant de la vinflunine et trastuzumab
PCT/EP2008/056620 WO2008145697A1 (fr) 2007-05-31 2008-05-29 Thérapie combinée comprenant la vinflunine et le trastuzumab pour le traitement du cancer

Publications (1)

Publication Number Publication Date
NO20093536L true NO20093536L (no) 2009-12-16

Family

ID=38353425

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20093536A NO20093536L (no) 2007-05-31 2009-12-16 Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab

Country Status (18)

Country Link
US (1) US20100196363A1 (fr)
EP (2) EP1997534A1 (fr)
JP (1) JP2010528091A (fr)
KR (1) KR20100017752A (fr)
CN (1) CN101687104A (fr)
AR (1) AR066778A1 (fr)
AU (1) AU2008257555A1 (fr)
BR (1) BRPI0812280A2 (fr)
CA (1) CA2689664A1 (fr)
CL (1) CL2008001589A1 (fr)
IL (1) IL202393A0 (fr)
MX (1) MX2009012874A (fr)
NO (1) NO20093536L (fr)
RU (1) RU2009146882A (fr)
TN (1) TN2009000490A1 (fr)
TW (1) TW200908976A (fr)
WO (1) WO2008145697A1 (fr)
ZA (1) ZA200908247B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CA2907776C (fr) 2013-04-16 2020-04-14 Genentech, Inc. Variantes de pertuzumab et leur evaluation
WO2018007554A1 (fr) * 2016-07-06 2018-01-11 Pierre Fabre Medicament Combinaison pharmaceutique comprenant la vinflunine et l'inhibiteur de pd1 et/ou de pdl1
CA3047349C (fr) 2017-01-17 2020-09-22 Genentech, Inc. Formulations sous-cutanees d'anticorps her2
MX388169B (es) 2017-03-02 2025-03-19 Genentech Inc Pertuzumab para usarse en el tratamiento de cáncer de mama her2 positivo.
CN115916834A (zh) 2020-06-29 2023-04-04 基因泰克公司 帕妥珠单抗加曲妥珠单抗的固定剂量组合

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation

Also Published As

Publication number Publication date
RU2009146882A (ru) 2011-07-10
IL202393A0 (en) 2010-06-30
CL2008001589A1 (es) 2009-03-06
BRPI0812280A2 (pt) 2014-11-18
KR20100017752A (ko) 2010-02-16
AR066778A1 (es) 2009-09-09
JP2010528091A (ja) 2010-08-19
EP2164573A1 (fr) 2010-03-24
WO2008145697A1 (fr) 2008-12-04
CA2689664A1 (fr) 2008-12-04
TN2009000490A1 (en) 2011-03-31
TW200908976A (en) 2009-03-01
CN101687104A (zh) 2010-03-31
EP1997534A1 (fr) 2008-12-03
ZA200908247B (en) 2010-10-27
US20100196363A1 (en) 2010-08-05
AU2008257555A1 (en) 2008-12-04
MX2009012874A (es) 2010-03-31

Similar Documents

Publication Publication Date Title
NO20093536L (no) Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
NO20092637L (no) Fremgangsmater for behandling
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA201201400A1 (ru) Композиции и способы лечения аутоиммунных и других заболеваний
EA201170521A1 (ru) Новые соединения
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
BRPI0821779A2 (pt) tratamento terapêutico de câncer
CY2016015I1 (el) Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA201170834A1 (ru) Соединения, пригодные для ингибирования chk1
EA201791669A2 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
CY2014006I2 (el) Μεθοδοι θεραπευτικης αγωγης χρησιμοποιωντας γλυκοπεγκυλιωμενο g-csf
HRP20150449T1 (xx) Metode lijeäśenja multiplog mijeloma primjenom kombiniranih terapija temeljenih na anti-cs1 antitijelima
EA201370208A1 (ru) Формы рифаксимина и их применение
EA201370071A1 (ru) Способы и композиции для лечения рака легких
EA201001865A1 (ru) Противовоспалительные агенты
ATE532789T1 (de) Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
MX2012010212A (es) Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer.
EA201170344A1 (ru) Азаиндольные ингибиторы iap
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application